Cancer Metabolism

Genetic alterations and epigenetic modifications of cancer cells result in cellular metabolic pathways that are different in comparison to normal cells. Due to the inherent genetic instability of cancer cells, tumors are heterogeneous with a myriad microenvironments and multiple altered metabolic pathways, which could provide useful cancer therapeutic targets.

Cancer Metabolism Products Targets

Products for Cancer Metabolism - Page 2

Cat.No. Product Name Information/Activity
BCC7938 STF 31 STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 μM).
BCN1259 D-(+)-Glucose Dextrose, a simple sugar (monosaccharide), is an important carbohydrate in biology.
BCC6506 BPTES BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
BCC4048 2-Deoxy-D-glucose 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
BCC2319 Atorvastatin Calcium Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
BCC2317 Fluvastatin Sodium Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
BCN1060 Lovastatin Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
BCN2568 Mevastatin Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
BCC3842 Pitavastatin Calcium Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
BCC2321 Pravastatin sodium Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.